InVivo Therapeutics Corporation
335 articles with InVivo Therapeutics Corporation
InVivo Therapeutics Announces Appointment of Richard Christopher as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Prior to joining InVivo, Mr. Christopher was the Chief Financial Officer of iCAD, Inc., a Nasdaq-listed company with a focus on therapies and solutions for the early identification and treatment of cancer.
Dr. Toselli’s presentation will discuss recent company updates.
11/27/2018Pancreatic cancer is currently rated as the third-leading cause of cancer-related deaths in the U.S., and is projected to be the second by 2020. It’s a notoriously difficult cancer to treat and is typically diagnosed so late in the game that it has metastasized throughout the body.
- Announces Western Institutional Review Board Approval for Select INSPIRE 2.0 Study Sites -
Aims to evaluate the preclinical safety and feasibility of the Neuro-Spinal Scaffold™ with stem cells
InVivo Therapeutics Announces Publication of Neuro-Spinal Scaffold Preclinical Data in Peer-Reviewed Journal Biomaterials
Supports INSPIRE clinical investigation of the Neuro-Spinal Scaffold
InVivo Therapeutics Announces Presentation at the Ladenburg Thalmann 2018 Healthcare Conference and Provides Business Update
InVivo Therapeutics Holdings Corp. today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 9:30 am Eastern Time at the Sofitel Hotel in New York, New York.
InVivo Therapeutics Announces Complete 12-Month Data from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
InVivo Therapeutics Holdings Corp. today announced the complete 12-month results from the company’s single-arm INSPIRE study
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
VBI Vaccines Inc.
Significant Increase in Operating Efficiency; Operating Expenses Decreased by 59%
Announced the pricing of an underwritten public offering of 388,403 shares of its common stock
Progress Update on INSPIRE 2.0 Trial, Finance Officer Appointment
InVivo Therapeutics Announces Presentation of Complete Six-Month Primary Endpoint Results from the INSPIRE Study of the Investigational Neuro-Spinal Scaffold™ in Acute Thoracic Complete Spinal Cord Injury
- Findings Presented at the 2018 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting -
Announces Reverse Stock Split and Key Cost-Saving Initiatives
InVivo Therapeutics Announces Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”) Findings
The CONTEMPO study includes neurological recovery data from registries of spinal cord injury (SCI) patients with similar baseline characteristics to those in the INSPIRE study.
Richard Toselli, M.D., President and Chief Executive Officer of InVivo, commented, “InVivo is charting a new and exciting path forward based on collaboration with the FDA that has continued through 2017 and into this year."
InVivo Therapeutics Receives FDA Approval for Pivotal, Randomized, Controlled Trial of the Neuro-Spinal Scaffold™ in Patients with Acute Spinal Cord Injury
Study Designed to Enhance Clinical Evidence from INSPIRE Study and Support Potential Humanitarian Device Exemption (HDE) Submission
Dr. Toselli also has been appointed to the company’s Board of Directors and will continue to serve in his capacity as InVivo’s Chief Medical Officer, which role he assumed upon joining the company in July 2017.
With a trial on hold for more than six months, InVivo has been burning through cash and may not have enough financing to continue operations for much longer.
In consideration for entering into the purchase agreement, the company has issued shares of common stock to Lincoln Park as a commitment fee. The purchase agreement may be terminated by the company at any time, in its sole discretion.